Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a Healthcare company (Biotechnology) with a market capitalization of $2.3B. The Maz Rating grades it against the other companies in its sector.
Celldex Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $28.83, Celldex Therapeutics, Inc. trades at 20218.3x sales and 3.5x book value. Over the last twelve months it generated about $112000 of revenue and a net loss of $339M. It runs a gross margin of -662.5%, an operating margin of -298657.1% and a net margin of -275986.6%. It shows return on equity of -52.7%, return on invested capital of -50.5% and a free cash flow yield of -11.5%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 10.97. Over the past 52 weeks the share price ranged from $22.33 to $45.14, with a beta of 0.90.
Celldex Therapeutics, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 18 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.